---
title: "EMA accepted marketing authorization app for Cevira by Asieris; collaboration with Photocure."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277180648.md"
description: "Norwegian company Photocure ASA, specializing in bladder cancer solutions, revealed that its collaborator Asieris Pharmaceuticals (SSE: 688176) has reported the submission of a marketing authorization application (MAA) for Cevira® (APL-1702) aimed at treating high-grade conditions. The announcement was made on Feb. 27, 2026. The development signifies a significant move in the field of bladder cancer treatment."
datetime: "2026-02-27T10:06:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277180648.md)
  - [en](https://longbridge.com/en/news/277180648.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277180648.md)
generator: "portal-rs"
---

# EMA accepted marketing authorization app for Cevira by Asieris; collaboration with Photocure.

Norwegian company Photocure ASA, specializing in bladder cancer solutions, revealed that its collaborator Asieris Pharmaceuticals (SSE: 688176) has reported the submission of a marketing authorization application (MAA) for Cevira® (APL-1702) aimed at treating high-grade conditions. The announcement was made on Feb. 27, 2026. The development signifies a significant move in the field of bladder cancer treatment.

### Related Stocks

- [688176.CN](https://longbridge.com/en/quote/688176.CN.md)

## Related News & Research

- [WUXI APPTEC  Sells 4.23% Stake in WUXI XDC, Cashes In HKD3.9B](https://longbridge.com/en/news/297217460.md)
- [WUXI APPTEC Reportedly Sells 2.6% Stake in WUXI XDC for Up to HKD2.4B](https://longbridge.com/en/news/297110148.md)
- [Zealand Pharma (CPSE:ZEAL) Reports Weaker Earnings, Is It Still Below Fair Value?](https://longbridge.com/en/news/297245804.md)
- [FGMA Rises to No. 38 in BD+C's 2026 Top 200 Architecture Firms Ranking](https://longbridge.com/en/news/297187912.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**